Tirzepatide emerges a groundbreaking treatment agent for individuals facing type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://hassanrjrt455124.vblogetin.com/46629335/tirzepatide-a-new-frontier-in-diabetes-treatment